A
Alba Torrents de la Peña
Researcher at University of Amsterdam
Publications - 35
Citations - 3589
Alba Torrents de la Peña is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Epitope & Antibody. The author has an hindex of 20, co-authored 30 publications receiving 3034 citations. Previous affiliations of Alba Torrents de la Peña include Scripps Research Institute & University of Barcelona.
Papers
More filters
Journal ArticleDOI
A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies
Rogier W. Sanders,Rogier W. Sanders,Ronald Derking,Albert Cupo,Jean-Philippe Julien,Anila Yasmeen,Natalia de Val,Helen J. Kim,Claudia Blattner,Alba Torrents de la Peña,Jacob Korzun,Michael Golabek,Kevin de los Reyes,Thomas J. Ketas,Marit J. van Gils,C. Richter King,Ian A. Wilson,Andrew B. Ward,Per Johan Klasse,John P. Moore +19 more
TL;DR: The design and properties of soluble, cleaved SOSIP trimers based on the subtype A transmitted/founder strain, BG505, are described, which are highly stable and homogenous and closely resemble native virus spikes when visualized by negative stain electron microscopy (EM).
Journal ArticleDOI
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface
Jinghe Huang,Byong H. Kang,Marie Pancera,Jeong Hyun Lee,Tommy Tong,Yu Feng,Hiromi Imamichi,Ivelin S. Georgiev,Gwo-Yu Chuang,Aliaksandr Druz,Nicole A. Doria-Rose,Leo B. Laub,Kwinten Sliepen,Marit J. van Gils,Alba Torrents de la Peña,Ronald Derking,Per Johan Klasse,Stephen A. Migueles,Robert T. Bailer,Munir Alam,Pavel Pugach,Barton F. Haynes,Richard T. Wyatt,Rogier W. Sanders,James M. Binley,Andrew B. Ward,John R. Mascola,Peter D. Kwong,Mark Connors +28 more
TL;DR: A broad and extremely potent HIV-specific monoclonal antibody, termed 35O22, which binds a novel HIV-1 envelope glycoprotein (Env) epitope, which represents a novel site of vulnerability on HIV Env, which serum analysis indicates to be commonly elicited by natural infection.
Journal ArticleDOI
Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers.
Claudia Blattner,Jeong Hyun Lee,Kwinten Sliepen,Ronald Derking,Emilia Falkowska,Alba Torrents de la Peña,Albert Cupo,Jean-Philippe Julien,Marit J. van Gils,Peter Lee,Wenjie Peng,James C. Paulson,Pascal Poignard,Dennis R. Burton,John P. Moore,Rogier W. Sanders,Rogier W. Sanders,Ian A. Wilson,Andrew B. Ward +18 more
TL;DR: This work defines and structurally characterize a unique epitope on Env that is recognized by a recently discovered family of human monoclonal antibodies (PGT151-PGT158), and compares the structural and functional properties of membrane-extracted Env trimers from several clades with those of the soluble, cleaved SOSIP gp140 trimer.
Journal ArticleDOI
Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes
Steven W. de Taeye,Gabriel Ozorowski,Alba Torrents de la Peña,Miklos Guttman,Jean-Philippe Julien,Tom L.G.M. van den Kerkhof,Judith A. Burger,Laura K. Pritchard,Pavel Pugach,Anila Yasmeen,Jordan C. Crampton,Joyce K. Hu,Ilja Bontjer,Jonathan L. Torres,Heather Arendt,Joanne DeStefano,Wayne C. Koff,Hanneke Schuitemaker,Dirk Eggink,Ben Berkhout,Hansi J. Dean,Celia C. LaBranche,Shane Crotty,Max Crispin,David C. Montefiori,Per Johan Klasse,Kelly K. Lee,John P. Moore,Ian A. Wilson,Andrew B. Ward,Rogier W. Sanders,Rogier W. Sanders +31 more
TL;DR: Stabilized, closed trimers might be useful components of vaccines aimed at inducing bNAbs, and induced similar autologous Tier-1B or Tier-2 NAb titers to those elicited by the corresponding wild-type trimers but lower levels of V3-directed Tier- 1A NAbs in rabbits.
Journal ArticleDOI
Elicitation of Robust Tier 2 Neutralizing Antibody Responses in Nonhuman Primates by HIV Envelope Trimer Immunization Using Optimized Approaches.
Matthias Pauthner,Colin Havenar-Daughton,Colin Havenar-Daughton,Devin Sok,Joseph P. Nkolola,Joseph P. Nkolola,Raiza Bastidas,Archana V. Boopathy,Diane G. Carnathan,Diane G. Carnathan,Diane G. Carnathan,Abishek Chandrashekar,Kimberly M. Cirelli,Kimberly M. Cirelli,Christopher A. Cottrell,Alexey Eroshkin,Alexey Eroshkin,Javier Guenaga,Kirti Kaushik,Kirti Kaushik,Daniel W. Kulp,Jinyan Liu,Jinyan Liu,Laura E. McCoy,Aaron L. Oom,Aaron L. Oom,Aaron L. Oom,Gabriel Ozorowski,Kai W. Post,Kai W. Post,Shailendra Kumar Sharma,Jon M. Steichen,Steven W. de Taeye,Talar Tokatlian,Talar Tokatlian,Alba Torrents de la Peña,Salvatore T. Butera,Celia C. LaBranche,David C. Montefiori,Guido Silvestri,Guido Silvestri,Guido Silvestri,Ian A. Wilson,Darrell J. Irvine,Rogier W. Sanders,Rogier W. Sanders,William R. Schief,Andrew B. Ward,Richard T. Wyatt,Dan H. Barouch,Dan H. Barouch,Dan H. Barouch,Shane Crotty,Shane Crotty,Shane Crotty,Dennis R. Burton +55 more
TL;DR: This study identifies protocols for rapid and consistent generation of tier 2 nAbs, providing a framework for future pre‐clinical and clinical vaccine studies targeting nAb elicitation and identified immunogens that minimized non‐neutralizing V3 responses and demonstrated that continuous immunogen delivery could enhance nAb responses.